{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T04:01:01Z","timestamp":1792123261395,"version":"4.4.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T00:00:00Z","timestamp":1744070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T00:00:00Z","timestamp":1744070400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Juan Rod\u00e9s"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1038\/s41409-025-02562-w","type":"journal-article","created":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T04:42:57Z","timestamp":1744087377000},"page":"832-840","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["GvHD prophylaxis with tacrolimus, sirolimus, and mycophenolate mofetil after reduced intensity conditioning hematopoietic stem cell allogeneic transplantation"],"prefix":"10.1038","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1908-5596","authenticated-orcid":false,"given":"L.","family":"Lopez-Corral","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Bl\u00e1zquez-Go\u00f1i","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"P\u00e9rez-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"FM","family":"Mart\u00edn-Dom\u00ednguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Cabero Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Rodr\u00edguez-Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7586-4792","authenticated-orcid":false,"given":"M.","family":"Cabrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Espigado-Tocino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AA","family":"Mart\u00edn L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Parody-Porras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Baile Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7487-3793","authenticated-orcid":false,"given":"T.","family":"Caballero-Vel\u00e1zquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Cort\u00e9s-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Soria-Saldise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Avenda\u00f1o Pita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Alcalde-Mellado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Garc\u00eda Bacelar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2237-6733","authenticated-orcid":false,"given":"E.","family":"Rodr\u00edguez-Arbol\u00ed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2949-0627","authenticated-orcid":false,"given":"M.","family":"L\u00f3pez Parra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JF","family":"Falantes-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7972-5666","authenticated-orcid":false,"given":"A.","family":"Navarro-Bail\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8191-0046","authenticated-orcid":false,"given":"L.","family":"V\u00e1zquez L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0639-574X","authenticated-orcid":false,"given":"V.","family":"Escamilla-G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3616-6101","authenticated-orcid":false,"given":"F.","family":"S\u00e1nchez-Guijo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JA","family":"P\u00e9rez-Sim\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,8]]},"reference":[{"key":"2562_CR1","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1038\/s41409-022-01691-w","volume":"57","author":"JA Snowden","year":"2022","unstructured":"Snowden JA, S\u00e1nchez-Ortega I, Corbacioglu S, Basak GW, Chabannon C, de la Camara R, et al. Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022. Bone Marrow Transpl. 2022;57:1217\u201339.","journal-title":"Bone Marrow Transpl"},{"key":"2562_CR2","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1038\/s41409-022-01604-x","volume":"57","author":"JR Passweg","year":"2022","unstructured":"Passweg JR, Baldomero H, Chabannon C, Corbacioglu S, de la C\u00e1mara R, Dolstra H, et al. Impact of the SARS-CoV-2 pandemic on hematopoietic cell transplantation and cellular therapies in Europe 2020: a report from the EBMT activity survey. Bone Marrow Transpl. 2022;57:742\u201352.","journal-title":"Bone Marrow Transpl"},{"key":"2562_CR3","doi-asserted-by":"publisher","first-page":"6283","DOI":"10.1182\/bloodadvances.2020003418","volume":"4","author":"O Penack","year":"2020","unstructured":"Penack O, Peczynski C, Mohty M, Yakoub-Agha I, Styczynski J, Montoto S, et al. How much has allogeneic stem cell transplant\u2013related mortality improved since the 1980s? A retrospective analysis from the EBMT. Blood Adv. 2020;4:6283\u201390.","journal-title":"Blood Adv"},{"key":"2562_CR4","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1182\/blood-2011-06-364265","volume":"119","author":"M Jagasia","year":"2012","unstructured":"Jagasia M, Arora M, Flowers MED, Chao NJ, McCarthy PL, Cutler CS, et al. Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood. 2012;119:296\u2013307.","journal-title":"Blood"},{"key":"2562_CR5","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","volume":"388","author":"J Bola\u00f1os-Meade","year":"2023","unstructured":"Bola\u00f1os-Meade J, Hamadani M, Wu J, Al Malki MM, Martens MJ, Runaas L, et al. Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis. N Engl J Med. 2023;388:2338\u201348.","journal-title":"N Engl J Med"},{"key":"2562_CR6","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1182\/bloodadvances.2020003779","volume":"5","author":"N Bejanyan","year":"2021","unstructured":"Bejanyan N, Pidala JA, Wang X, Thapa R, Nishihori T, Elmariah H, et al. A phase 2 trial of GVHD prophylaxis with PTCy, sirolimus, and MMF after peripheral blood haploidentical transplantation. Blood Adv. 2021;5:1154\u201363.","journal-title":"Blood Adv"},{"key":"2562_CR7","doi-asserted-by":"publisher","first-page":"e132","DOI":"10.1016\/S2352-3026(18)30221-7","volume":"6","author":"J Bola\u00f1os-Meade","year":"2019","unstructured":"Bola\u00f1os-Meade J, Reshef R, Fraser R, Fei M, Abhyankar S, Al-Kadhimi Z, et al. Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203). Lancet Haematol. 2019;6:e132\u201343.","journal-title":"Lancet Haematol"},{"key":"2562_CR8","doi-asserted-by":"publisher","first-page":"3378","DOI":"10.1182\/bloodadvances.2021005847","volume":"6","author":"AEC Broers","year":"2022","unstructured":"Broers AEC, de Jong CN, Bakunina K, Hazenberg MD, van Marwijk Kooy M, de Groot MR, et al. Posttransplant cyclophosphamide for prevention of graft-versus-host disease: results of the prospective randomized HOVON-96 trial. Blood Adv. 2022;6:3378\u201385.","journal-title":"Blood Adv"},{"key":"2562_CR9","doi-asserted-by":"publisher","first-page":"776.e1","DOI":"10.1016\/j.jtct.2021.05.023","volume":"27","author":"R Greco","year":"2021","unstructured":"Greco R, Lorentino F, Albanese S, Lupo Stanghellini MT, Giglio F, Piemontese S, et al. Posttransplantation cyclophosphamide- and sirolimus-based graft-versus-host-disease prophylaxis in allogeneic stem cell transplant. Transpl Cell Ther. 2021;27:776.e1\u2013776.e13.","journal-title":"Transpl Cell Ther"},{"key":"2562_CR10","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1182\/blood-2014-02-514778","volume":"124","author":"B Gyurkocza","year":"2014","unstructured":"Gyurkocza B, Sandmaier BM. Conditioning regimens for hematopoietic cell transplantation: one size does not fit all. Blood. 2014;124:344\u201353.","journal-title":"Blood"},{"key":"2562_CR11","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.bbmt.2009.03.017","volume":"15","author":"VT Ho","year":"2009","unstructured":"Ho VT, Aldridge J, Kim HT, Cutler C, Koreth J, Armand P, et al. Comparison of tacrolimus and sirolimus (Tac\/Sir) versus Tacrolimus, sirolimus, and mini-methotrexate (Tac\/Sir\/MTX) as acute graft-versus-host disease prophylaxis after reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation. Biol Blood Marrow Transplant. 2009;15:844\u201350.","journal-title":"Biol Blood Marrow Transplant"},{"key":"2562_CR12","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1182\/blood.2020005338","volume":"136","author":"B Kornblit","year":"2020","unstructured":"Kornblit B, Storer BE, Andersen NS, Maris MB, Chauncey TR, Petersdorf EW, et al. Sirolimus with CSP and MMF as GVHD prophylaxis for allogeneic transplantation with HLA antigen\u2013mismatched donors. Blood. 2020;136:1499\u2013506.","journal-title":"Blood"},{"key":"2562_CR13","first-page":"2062","volume":"96","author":"RA Nash","year":"2000","unstructured":"Nash RA, Antin JH, Karanes C, Fay JW, Avalos BR, Yeager AM, et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood. 2000;96:2062\u20138. Available from: http:\/\/ashpublications.org\/blood\/article-pdf\/96\/6\/2062\/1667677\/h8180002062.pdf.","journal-title":"Blood"},{"key":"2562_CR14","doi-asserted-by":"publisher","first-page":"e409","DOI":"10.1016\/S2352-3026(19)30088-2","volume":"6","author":"BM Sandmaier","year":"2019","unstructured":"Sandmaier BM, Kornblit B, Storer BE, Olesen G, Maris MB, Langston AA, et al. Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial. Lancet Haematol. 2019;6:e409\u201318.","journal-title":"Lancet Haematol"},{"key":"2562_CR15","doi-asserted-by":"publisher","first-page":"526","DOI":"10.3324\/haematol.2012.065599","volume":"98","author":"JA Perez-Simon","year":"2013","unstructured":"Perez-Simon JA, Martino R, Parody R, Cabrero M, Lopez-Corral L, Valcarcel D, et al. The combination of sirolimus plus tacrolimus improves outcome after reduced-intensity conditioning, unrelated donor hematopoietic stem cell transplantation compared with cyclosporine plus mycofenolate. Haematologica. 2013;98:526\u201332.","journal-title":"Haematologica"},{"key":"2562_CR16","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1182\/blood.V91.3.756","volume":"91","author":"S Slavin","year":"1998","unstructured":"Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 1998;91:756\u201363.","journal-title":"Blood"},{"key":"2562_CR17","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1056\/NEJM198603203141201","volume":"314","author":"R Storb","year":"1986","unstructured":"Storb R, Deeg HJ, Whitehead J, Appelbaum F, Beatty P, Bensinger W, et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med. 1986;314:729\u201335.","journal-title":"N Engl J Med"},{"key":"2562_CR18","first-page":"2303","volume":"92","author":"V Ratanatharathorn","year":"1998","unstructured":"Ratanatharathorn V, Nash RA, Przepiorka D, Devine SM, Klein JL, Weisdorf D, et al. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood. 1998;92:2303\u201314. Available from: http:\/\/ashpublications.org\/blood\/article-pdf\/92\/7\/2303\/1448702\/2303.pdf","journal-title":"Blood"},{"key":"2562_CR19","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.bbmt.2018.08.018","volume":"25","author":"S Chhabra","year":"2019","unstructured":"Chhabra S, Liu Y, Hemmer MT, Costa L, Pidala JA, Couriel DR, et al. Comparative analysis of calcineurin inhibitor\u2013based methotrexate and mycophenolate mofetil\u2013containing regimens for prevention of graft-versus-host disease after reduced-intensity conditioning allogeneic transplantation. Biol Blood Marrow Transplant. 2019;25:73\u201385.","journal-title":"Biol Blood Marrow Transplant"},{"key":"2562_CR20","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/bmt.2014.220","volume":"50","author":"R Parody","year":"2015","unstructured":"Parody R, Lopez-Corral L, Godino OL, Cadenas IG, Martinez AP, Vazquez L, et al. GVHD prophylaxis with sirolimus-tacrolimus may overcome the deleterious effect on survival of HLA mismatch after reduced-intensity conditioning allo-SCT. Bone Marrow Transpl. 2015;50:121\u20136.","journal-title":"Bone Marrow Transpl"},{"key":"2562_CR21","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1097\/00007890-199102000-00041","volume":"51","author":"PM Kimball","year":"1991","unstructured":"Kimball PM, Kerman RH, Kahan BD. Production of synergistic but nonidentical mechanisms of immunosuppression by rapamycin and cyclosporine. Transplantation. 1991;51:486\u201390.","journal-title":"Transplantation"},{"key":"2562_CR22","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1097\/00007890-199101000-00038","volume":"51","author":"BD Kahan","year":"1991","unstructured":"Kahan BD, Gibbons S, Tejpal N, Stepkowski SM, Chou TC. Synergistic interactions of cyclosporine and rapamycin to inhibit immune performances of normal human peripheral blood lymphocytes in vitro. Transplantation. 1991;51:232\u20139.","journal-title":"Transplantation"},{"key":"2562_CR23","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.bbmt.2015.09.001","volume":"22","author":"AC Harris","year":"2016","unstructured":"Harris AC, Young R, Devine S, Hogan WJ, Ayuk F, Bunworasate U, et al. International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the Mount Sinai Acute GVHD International Consortium. Biol Blood Marrow Transplant. 2016;22:4\u201310.","journal-title":"Biol Blood Marrow Transplant"},{"key":"2562_CR24","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","volume":"21","author":"MH Jagasia","year":"2015","unstructured":"Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant. 2015;21:389\u2013401.e1.","journal-title":"Biol Blood Marrow Transplant"},{"key":"2562_CR25","doi-asserted-by":"publisher","first-page":"835","DOI":"10.3324\/haematol.2018.202754","volume":"104","author":"G Fatobene","year":"2019","unstructured":"Fatobene G, Storer BE, Salit RB, Lee SJ, Martin PJ, Cheng GS, et al. Disability related to chronic graft - versus -host disease after alternative donor hematopoietic cell transplantation. Haematologica. 2019;104:835\u201343.","journal-title":"Haematologica"},{"key":"2562_CR26","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/s41409-023-01992-8","volume":"58","author":"M Mohty","year":"2023","unstructured":"Mohty M, Malard F, Alaskar AS, Aljurf M, Arat M, Bader P, et al. Diagnosis and severity criteria for sinusoidal obstruction syndrome\/veno-occlusive disease in adult patients: a refined classification from the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transpl. 2023;58:749\u201354.","journal-title":"Bone Marrow Transpl"},{"key":"2562_CR27","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1093\/cid\/ciae321","volume":"79","author":"P Ljungman","year":"2024","unstructured":"Ljungman P, Chemaly RF, Khawaya F, Alain S, Avery R, Badshah C, et al. Consensus definitions of cytomegalovirus (CMV) infection and disease in transplant patients including resistant and refractory CMV for use in clinical trials: 2024 update from the transplant associated virus infections forum. Clin Infect Dis. 2024;79:787\u201394.","journal-title":"Clin Infect Dis"},{"key":"2562_CR28","doi-asserted-by":"publisher","first-page":"803","DOI":"10.3324\/haematol.2016.144428","volume":"101","author":"J Styczynski","year":"2016","unstructured":"Styczynski J, van der Velden W, Fox CP, Engelhard D, de la Camara R, Cordonnier C, et al. Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines. Haematologica. 2016;101:803\u201311.","journal-title":"Haematologica"},{"key":"2562_CR29","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1111\/tid.12022","volume":"14","author":"S Matthes-Martin","year":"2012","unstructured":"Matthes-Martin S, Feuchtinger T, Shaw PJ, Engelhard D, Hirsch HH, Cordonnier C, et al. European guidelines for diagnosis and treatment of adenovirus infection in leukemia and stem cell transplantation: summary of ECIL-4 (2011). Transpl Infect Dis. 2012;14:555\u201363.","journal-title":"Transpl Infect Dis"},{"key":"2562_CR30","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1086\/588660","volume":"46","author":"B De Pauw","year":"2008","unstructured":"De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer\/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC\/MSG) Consensus Group. Clin Infect Dis. 2008;46:1813\u201321.","journal-title":"Clin Infect Dis"},{"key":"2562_CR31","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jtct.2022.11.015","volume":"29","author":"ML Schoettler","year":"2023","unstructured":"Schoettler ML, Carreras E, Cho B, Dandoy CE, Ho VT, Jodele S, et al. Harmonizing definitions for diagnostic criteria and prognostic assessment of transplantation-associated thrombotic microangiopathy: a report on behalf of the European Society for Blood and Marrow Transplantation, American Society for Transplantation and Cellular Therapy, Asia-Pacific Blood and Marrow Transplantation Group, and Center for International Blood and Marrow Transplant Research. Transpl Cell Ther. 2023;29:151\u201363.","journal-title":"Transpl Cell Ther"},{"key":"2562_CR32","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1093\/jac\/dky158","volume":"73","author":"S Cesaro","year":"2018","unstructured":"Cesaro S, Dalianis T, Hanssen Rinaldo C, Koskenvuo M, Pegoraro A, Einsele H, et al. ECIL guidelines for the prevention, diagnosis and treatment of BK polyomavirus-associated haemorrhagic cystitis in haematopoietic stem cell transplant recipients. J Antimicrob Chemother. 2018;73:12\u201321.","journal-title":"J Antimicrob Chemother"},{"key":"2562_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2020.100792","volume":"48","author":"N Martinez-Cibrian","year":"2021","unstructured":"Martinez-Cibrian N, Zeiser R, Perez-Simon JA. Graft-versus-host disease prophylaxis: pathophysiology-based review on current approaches and future directions. Blood Rev. 2021;48:100792.","journal-title":"Blood Rev"},{"key":"2562_CR34","doi-asserted-by":"publisher","first-page":"e147","DOI":"10.1016\/S2352-3026(23)00342-3","volume":"11","author":"O Penack","year":"2024","unstructured":"Penack O, Marchetti M, Aljurf M, Arat M, Bonifazi F, Duarte RF, et al. Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. Lancet Haematol. 2024;11:e147\u201359.","journal-title":"Lancet Haematol"},{"key":"2562_CR35","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1056\/NEJMoa1506002","volume":"374","author":"N Kr\u00f6ger","year":"2016","unstructured":"Kr\u00f6ger N, Solano C, Wolschke C, Bandini G, Patriarca F, Pini M, et al. Antilymphocyte globulin for prevention of chronic graft-versus-host disease. N Engl J Med. 2016;374:43\u201353.","journal-title":"N Engl J Med"},{"key":"2562_CR36","doi-asserted-by":"publisher","first-page":"3456","DOI":"10.1182\/blood.V98.12.3456","volume":"98","author":"L Luznik","year":"2001","unstructured":"Luznik L, Jalla S, Engstrom LW, Iannone R, Fuchs EJ. Durable engraftment of major histocompatibility complex\u2013incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide. Blood. 2001;98:3456\u201364.","journal-title":"Blood"},{"key":"2562_CR37","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1053\/bbmt.2002.v8.pm11939602","volume":"8","author":"L Luznik","year":"2002","unstructured":"Luznik L, Engstrom LW, Iannone R, Fuchs EJ. Posttransplantation cyclophosphamide facilitates engraftment of major histocompatibility complex-identical allogeneic marrow in mice conditioned with low-dose total body irradiation. Biol Blood Marrow Transplant. 2002;8:131\u20138.","journal-title":"Biol Blood Marrow Transplant"},{"key":"2562_CR38","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1038\/s41409-020-0921-6","volume":"55","author":"J Montoro","year":"2020","unstructured":"Montoro J, Pi\u00f1ana JL, Hern\u00e1ndez-Boluda JC, Hernani R, Lorenzo I, P\u00e9rez A, et al. Uniform graft-versus-host disease prophylaxis with posttransplant cyclophosphamide, sirolimus, and mycophenolate mofetil following hematopoietic stem cell transplantation from haploidentical, matched sibling and unrelated donors. Bone Marrow Transpl. 2020;55:2147\u201359.","journal-title":"Bone Marrow Transpl"},{"key":"2562_CR39","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1200\/JCO.20.03502","volume":"39","author":"BE Shaw","year":"2021","unstructured":"Shaw BE, Jimenez-Jimenez AM, Burns LJ, Logan BR, Khimani F, Shaffer BC, et al. National Marrow Donor Program-sponsored multicenter, phase II trial of HLA-mismatched unrelated donor bone marrow transplantation using post-transplant cyclophosphamide. J Clin Oncol. 2021;39:1971\u201382.","journal-title":"J Clin Oncol"},{"key":"2562_CR40","doi-asserted-by":"publisher","first-page":"2885","DOI":"10.1111\/ajt.14754","volume":"18","author":"JL Pi\u00f1ana","year":"2018","unstructured":"Pi\u00f1ana JL, Perez-Pitarch A, Guglieri-Lopez B, Gim\u00e9nez E, Hernandez-Boluda JC, Terol MJ, et al. Sirolimus exposure and the occurrence of cytomegalovirus DNAemia after allogeneic hematopoietic stem cell transplantation. Am J Transplant. 2018;18:2885\u201394.","journal-title":"Am J Transplant"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02562-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02562-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02562-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T12:18:38Z","timestamp":1749557918000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02562-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,8]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["2562"],"URL":"https:\/\/doi.org\/10.1038\/s41409-025-02562-w","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,8]]},"assertion":[{"value":"21 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}